anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In reproduction studies in rats and rabbits, adverse effects on the fetus were observed mainly at dose levels that were toxic to dams. Tacrolimus at oral doses of 0.32 and 1.0 mg/kg during organogenesis in rabbits was associated with maternal toxicity as well as an increase in incidence of abortions; these doses are equivalent to 0.5 – 1X and 1.6 – 3.3X the recommended clinical dose range (0.1 – 0.2 mg/kg) based on body surface area corrections. At the higher dose only, an increased incidence of malformations and developmental variations was also seen. Tacrolimus, at oral doses of 3.2 mg/kg during organogenesis in rats, was associated with maternal toxicity and caused an increase in late resorptions, decreased numbers of live births, and decreased pup weight and viability. Tacrolimus, given orally at 1.0 and 3.2 mg/kg (equivalent to 0.7 – 1.4X and 2.3 – 4.6X the recommended clinical dose range based on body surface area corrections) to pregnant rats after organogenesis and during lactation, was associated with reduced pup weights.

No reduction in male or female fertility was evident.

There are no adequate and well-controlled studies in pregnant women. Tacrolimus is transferred across the placenta. The use of tacrolimus during pregnancy has been associated with neonatal hyperkalemia and renal dysfunction. Prograf should be used during pregnancy only if the potential benefit to the mother justifies potential risk to the fetus.
In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.
The efficacy of ENTADFI is based on an adequate and well-controlled study of tadalafil co-administered with finasteride. Below is the description of this study.

Tadalafil for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an enlarged prostate (>30 cc) for up to 26 weeks. A double-blinded, parallel-design study of 26 weeks duration randomized 696 men to initiate either tadalafil 5 mg with finasteride 5 mg or placebo with finasteride 5 mg. The study population had a mean age of 64 years (range 46-86). Patients with multiple co-morbid conditions such as erectile dysfunction, diabetes mellitus, hypertension, and other cardiovascular disease were included.

Tadalafil and finasteride administered together demonstrated statistically significant improvement in the signs and symptoms of BPH compared to placebo with finasteride, as measured by the total symptom score (IPSS) at 12 weeks, the primary study endpoint (see Table 12). Key secondary endpoints demonstrated improvement in total IPSS starting at the first scheduled observation at week 4 (tadalafil -4.0, placebo -2.3: p<.001) and the score remained decreased through 26 weeks (tadalafil -5.5, placebo -4.5; p=.022). However, the magnitude of the treatment difference between placebo/finasteride and tadalafil/finasteride decreased from 1.7 points at Week 4 to 1.0 point at Week 26, as shown in Table 12 and in Figure 4. The incremental benefit of ENTADFI beyond 26 weeks is unknown.

Figure 4: Mean Total IPSS Changes By Visit in BPH Patients Taking Tadalafil Together with Finasteride
In cardiovascular homeostasis thyroid hormone plays an important role. We planned to study the changes in thyroid hormone profile in acute coronary syndrome patients admitted in the coronary care unit and compare them between two groups: unstable angina/non-ST elevated Myocardial infarction (UA/NSTEMI) and ST elevated Myocardial infarction (STEMI). This study was a hospital based descriptive cross sectional study which was conducted from 01 March 2018 to 01 February 2019 in Coronary Care Unit of Bangladesh Medical College Hospital and laboratory tests were done in Microbiology Department of Bangladesh Medical College, Dhaka, Bangladesh. Eighty three cases of acute coronary syndromes were taken for the study. Troponin-I was measured as cardiac marker, Electrocardiogram, Complete blood count, blood glucose level, Blood urea, serum creatinine, serum electrolytes, Fasting lipid profile, Thyroid profile, Echocardiography 2D were done. Most of the respondents were distributed in age group 46-60 years where 34(64.15%) male and 19(35.85%) female. Out of 83 Acute Coronary Syndrome (ACS) patients, 27(32.53%) hypertensive, 22(26.50%) diabetic and 16(19.27%) were Chronic kidney disease (CKD). Abnormal lipid profile was present in 30(43.47%) patients. Among total 52 male and 31 female 9(17.30%) male and 6(19.35%) female had abnormal thyroid function. We further elaborated abnormal thyroid function tests in STEMI group and UA/Non STEMI group of ACS patients. We found 10 patients in STEMI group and 5 patients in UA/Non STEMI group with abnormal thyroid function 29.41% and 10.20% respectively which was not statistically significant (p=0.025). This study depicts abnormality in thyroid hormone profile in 18.07% patients of ACS. Abnormal thyroid function increases risk of coronary artery disease. TSH level of ACS patients on hospital admission could be helpful to evaluate further prognosis of the disease.
Vasopressor therapy be titrated by the clinical team per usual SOC and UNMH Nursing Department Titration Guideline. using other available vasopressor agents (e.g., higher-dose norepinephrine, vasopressin, epinephrine, phenylephrine, and/or dopamine). To provide a comparator arm, patients in the SOC will have renin and DPP3 levels obtained at equivalent timepoints.
BACKGROUND: Among leukemia patients, sleep disruptions are prevalent and can profoundly affect their overall quality of life. Acupressure and foot reflexology, modalities rooted in traditional Chinese medicine, have garnered attention for their potential to address sleep disturbances and mitigate associated symptoms.
METHODS: This research utilized a randomized controlled trial with a pretest-posttest design involving 102 leukemia patients admitted to Imam Khomeini Hospital in Urmia. Participants were randomly allocated to 3 groups: acupressure (n = 34), reflexology (n = 34), or control (n = 34). Prior to the intervention, patients completed a demographic survey and the Pittsburgh Sleep Quality Index (PSQI) for baseline assessments. Acupressure involved stimulation of the SP6 point twice daily for 10 minutes over 4 weeks, while reflexology entailed daily 10-minute sessions with sweet almond oil on the soles for the same duration. The control group received standard care without additional interventions. Following the 4-week intervention period, post-intervention evaluations were conducted using identical measurement tools.
RESULTS: The findings underscored the efficacy of both acupressure and foot reflexology in significantly improving sleep quality within the intervention groups (P < .001). Initially, there were no notable differences in sleep quality among the 3 groups (P > .05). Subsequently, pairwise comparisons adjusted with Bonferroni corrections revealed significant disparities in sleep quality between the acupressure and reflexology groups compared to the control group (P < .001). However, post-intervention analysis indicated no statistically significant variance in enhancing sleep quality between the acupressure and foot reflexology groups (P < .05).
CONCLUSION: This study demonstrates that acupressure and foot reflexology interventions can enhance sleep quality in individuals with leukemia. These findings support the effectiveness of these complementary modalities, offering targeted relief and relaxation. While these non-invasive therapies show promise in improving well-being, further research is needed to confirm and expand upon these results due to study limitations.
COVID-19 has emerged as a global pandemic. It is mainly manifested as pneumonia which may deteriorate into severe respiratory failure. The major hallmark of the disease is the systemic inflammatory immune response characterized by Cytokine Storm (CS). CS is marked by elevated levels of inflammatory cytokines, mainly interleukin-6 (IL-6), IL-8, IL-10, tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Of these, IL-6 is found to be significantly associated with higher mortality. IL-6 is also a robust marker for predicting disease prognosis and deterioration of clinical profile. (1) IL-6 was detectable in the breath condensate of all the healthy non-smokers, but was significantly higher in the COPD patient. Exhaled breath condensate is totally non-invasive and highly acceptable to patients. The collection procedure has no effect on airway function or inflammation, and there is growing evidence that abnormalities in condensate composition may reflect biochemical changes in airway lining fluid. This method has been successfully used in previous studies to investigate several inflammatory markers in COPD and asthmatic patients. (2) Il-6 is produced in the lung by interstitial fibroblasts, alveolar macrophages, and large-vessel and bronchial epithelial cells. IL-6 levels are high in chronic inflammatory conditions of the lung, such as those due to allogeneic transplantation, bleomycin-induced fibrosis and a variety of human interstitial lung diseases. High levels of IL-6 have been found in the induced sputum of patients with COPD, particularly during exacerbation. Park et al. found increased IL-6 levels in the Bronchioalveolar lavage fluid of patients with non-specific interstitial pneumonia/fibrosis and in some patients with interstitial pneumonia. (3) Dowlati et al. have reported increased levels of IL-6 in the serum and BAL fluid of patients with lung cancer. (4) A recent study by Bhowmik et al. found increased IL-6 and IL-8 levels in the sputum of COPD patients with frequent exacerbations. (5) Also, at another study Exhaled interleukin-6 and leukotriene B4 levels may be useful noninvasive markers of airway inflammation in cigarette smokers. (6) These studies and our novel method after clinical trials may open the field for future therapies for covid-19 and post covid-19 lung fibrosis by inhaler transport medicines as a new challenge for overcome sequels of this pandemic. And this suggested new procedure for measurement of exhaled il-6 take us to study which is IL-6 is risky is IL-6 produced from airway or endocrine IL-6 or immune IL-6 From previous studies we need a procedure acceptable to patients and easy, noninvasive, sensitive he study involved 20 healthy controls and 20 patients with moderate to severe covid-19 according to cdc classifaction and 20 patients post covid-19 with lung fibrosis to estimate the measurment of interleukin-6 at exhaled condensate, this clinical randomized control study consists of 3 arms for 6 month ( all participants above 18 years non prgnant humans )
FIELD: cosmetic compositions. SUBSTANCE: cosmetic compositions may be used for washing and care of keratin materials such as hair, skin, eyelashes, eyebrows, nails and lips. Claimed cosmetic composition includes in cosmetically acceptable medium at least one copolymer of dimethicone with double bond and dimethicone with viscosity of 10 6 -100•10 6  cP, and at least one cation polymer. The invention also deals with a method of treating keratin fibers such as hair. Such a combination gives keratin materials new cosmetic properties such as smoothing, easiness, softness without increasing their fatness. EFFECT: increased efficiency. 13 cl
PURPOSE:To efficiently prepare a microcapsule, by a method wherein an electrolyte is added to a microcapsule dispersion in quantity of 8-100pts. by wt. of 100pts. of water compounded at the time of the coating of the microcapsule to dehydrate the microcapsule membrane. CONSTITUTION:A hydrophobic liquid droplet is used as a core substance and coated with a phase separated substance of hydrophilic colloid to form a microcapsule. Subsequently, an electrolyte is added to a liquid having said microcapsule dispersed therein in quantity of 8-100pts. by wt. of 100pts. of water compounded at the time of the coating of the microcapsule to dehydrate the microcapsule membrane. As the hydrophilic colloid, an aqueous solution containing gelatin and an anionic hydrophilic high-molecular substance is pref. As the hydrophobic core substance, there are paraffin oil, tallow and silicone oil and, as the electrolyte, there are sulfuric acid, hydrochloric acid, phosphoric acid, citric acid, tartaric acid or an alkali metal salt or ammonium compound thereof.
The present invention relates to a tricholsanthin mutant product with high-solube expression and a preparation method thereof. Compared with the natural trichosanthin, the trichosanthin mutant or a section or a derivate thereof at least lacks amino acid residues from the 242th position to the 247th position. The present invention provides a ribonucleic acid of the mutant or the section or the derivate thereof, and a carrier of the ribonucleic acid. The present invention also provides a gene engineering method for preparing the mutant or the section or the derivate thereof, and a medicine composition which comprises the mutant, the section or the derivate thereof. Compared with the natural trichosanthin, the present invention has the characteristic of great enhancement of fermentation yield, and thus, the present invention is suitable for actual large-scale industrialization application. The medicine composition which comprises the product can treat diseases of tumors, AIDS, extrauterine pregnancy, induction of labor in second trimester, and the like in modes of high efficiency and low toxicity.
A randomized controlled trial in a Norwegian context, involving an effect evaluation, a cost-benefit evaluation and a qualitative evaluation. Independent medical evaluation (IME) will be compared to treatment as usual (TAU). Independent medical evaluation (IME) will comprise a consultation with an independent general practitioner (IME GP) who will assess whether the sick listed worker has been given eligible and available opportunities in return to work follow-up in Norway. The independent medical evaluation general practitioner (IME GP) will write a short report that is sent to the treating general practitioner as input from a colleague. The report can be used in the follow-up of the sick listed participant. The participants in the treatment as usual (TAU) group will not receive any other follow-up than normal follow-up by the treating general practitioner. The qualitative evaluation will be conducted to gain insight into the experiences of the general practitioners and the participants.
PROBLEM TO BE SOLVED: To make it possible to supplement hepatic functions for all kinds of hepatic insufficiency and to preserve the supplements over a long period of time by forming hepatic tissue slices preservable at a prescribed temp. without losing their physiological activity from the liver of the fetus of the prescribed fetal age aseptically taken out of the pregnant swine and packing these slices into a selective permeable membrane capsule. SOLUTION: The fetus of the fetal age of >=70 days is aseptically taken out of the pregnant swine by cesarean section and the liver of the fetus is enucleated. This lever is rapidly washed with an antibotic-contg. phosphoric acid buffer soln. kept at about 4 deg.C and is cut to cubic slices of 0.5 to 5.0mm square by a laser knife. The cut slices are then subjected to washing to remove the blood cells and is immersed into a preserving liquid contg. 5.0 to 10.0% dimethyl sulfoxide or glycerol and 40.0 to 60.0% phosphoric acid buffer soln. to prevent freezing damage in such a manner that the preservation at <=-198 deg.C is made possible. The hepatic tissue slices 2 obtd. in such a manner are packed into a capsule consisting of the selective permeable membrane 1, by which the hepatic supplements 3 are formed.
The current invention relies on a process already provided in great detail in U.S. Pat. No. 60/437,507 and an associated CIP filed on May 23, 2003 and hereby incorporated by reference. However, it was noted during additional studies that if the Cushioning Beads™ were milled to a particle size between about 10 mesh and about 50 mesh and to a most preferred size of 30-40 mesh, the Cushioning Beads™ did not loose their ability to protect coated particles during compression, as would be expected because of the fine milling. Moreover, it was also discovered that tablets compressed from the milled Cushioning Beads™ immediately disperse in the mouth. A final advantage of the current invention is the improved hardness and friability. The invention produces a tablet of 2Kp or 20N hardness. A vast improvement because it allows for use of conventional manufacturing and packaging equipment.
Subjects will receive a SC dose of MVA 5x10\^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
Risk Summary

There is no information regarding the presence of fulvestrant in human milk, nor of its effects on milk production or breastfed infant. Fulvestrant can be detected in rat milk [see Data]. Because of the potential for serious adverse reactions in breastfed infants from fulvestrant, advise a lactating woman not to breastfeed during treatment with fulvestrant injection and for one year after the final dose. 

Data

Levels of fulvestrant were approximately 12-fold higher in milk than in plasma after exposure of lactating rats to a dose of 2 mg/kg. Drug exposure in rodent pups from fulvestrant-treated lactating dams was estimated as 10% of the administered dose. In a study in rats of fulvestrant at 10 mg/kg given twice or 15 mg/kg given once (less than the recommended human dose based on mg/m2) during lactation, offspring survival was slightly reduced.
Nifedipine is completely absorbed after oral administration. Plasma drug concentrations rise at a gradual, controlled rate after a nifedipine extended-release tablet dose and reach a plateau at approximately six hours after the first dose. For subsequent doses, relatively constant plasma concentrations at this plateau are maintained with minimal fluctuations over the 24-hour dosing interval. About a four-fold higher fluctuation index (ratio of peak to trough plasma concentration) was observed with the conventional immediate-release nifedipine capsule at t.i.d. dosing than with once daily nifedipine extended-release tablet. At steady-state, the bioavailability of the nifedipine extended-release tablet is 86% relative to nifedipine capsules. Administration of the nifedipine extended-release tablet in the presence of food slightly alters the early rate of drug absorption, but does not influence the extent of drug bioavailability. Markedly reduced gastrointestinal retention time over prolonged periods (i.e., short bowel syndrome), however, may influence the pharmacokinetic profile of the drug which could potentially result in lower plasma concentrations. Pharmacokinetics of nifedipine extended-release tablets are linear over the dose range of 30 to 180 mg in that plasma drug concentrations are proportional to dose administered. There was no evidence of dose dumping either in the presence or absence of food for over 150 subjects in pharmacokinetic studies.

Nifedipine is extensively metabolized to highly water-soluble, inactive metabolites, accounting for 60 to 80% of the dose excreted in the urine. The elimination half-life of nifedipine is approximately two hours. Only traces (less than 0.1% of the dose) of unchanged form can be detected in the urine. The remainder is excreted in the feces in metabolized form, most likely as a result of biliary excretion. Thus, the pharmacokinetics of nifedipine are not significantly influenced by the degree of renal impairment. Patients in hemodialysis or chronic ambulatory peritoneal dialysis have not reported significantly altered pharmacokinetics of nifedipine. Since hepatic biotransformation is the predominant route for the disposition of nifedipine, the pharmacokinetics may be altered in patients with chronic liver disease. Patients with hepatic impairment (liver cirrhosis) have a longer disposition half-life and higher bioavailability of nifedipine than healthy volunteers. The degree of serum protein binding of nifedipine is high (92 to 98%). Protein binding may be greatly reduced in patients with renal or hepatic impairment.

Following intravenous administration, clearance of nifedipine was decreased by 33% in elderly healthy subjects relative to young healthy subjects.
The invention relates to composition of a xylitol nicotine chewing gum and a belt-producing method thereof. The invention aims at providing a xylitol nicotine chewing gum and a producing method thereof, which is essentially used as a substitute of tobaccos for easing a craving for tobacco during abstaining from smoking or for chewing the gum instead of smoking in the situation that does not allow smoking. The gum of the invention has the advantages that: chewing the gum can ease the craving for tobacco, reduce the consumption of the tobaccos and prevent human body from being harmed by hazardous substances such as tar in the tobaccos by inhaling. The aim of quitting smoking is achieved by chewing the gum with different content nicotine from 4mg to 2mg and 1mg so as to gradually reducing the addiction to the nicotine and finally using a consolation type non-nicotine chewing gum. Since the nicotine chewing gum uses pure xylitol as the only sweetener (100 percent xylitol sweetener), the chewing of the gum does not harm teeth, but is good for oral health, and the gum with low calorie is also suitable for persons with diabetes. The main components of the xylitol nicotine chewing gum comprise: the xylitol, the nicotine, gum base, arabica gum, essence, glycerin and lecithin. The gum is characterized in that: the xylitol is adopted as the only sweetener, and the weight percentages of the components are: 40.0 to 99.0 percent of xylitol, 0.0 to 2.0 percent of nicotine, 30.0 to 60.0 percent of gum base, 0.1 to 10.0 percent of arabica gum and 0.0 to 8.0 percent of edible essence. The producing method is characterized by extruding raw materials for forming, namely, evenly mixing and extruding the main raw material and supplementaries for forming and coating with xylitol and arabica gum solution.
Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be \< 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.